Rivastigmine for dementia associated with Parkinson's disease.

By M. Emre, Dag Aarsland, A. Albanese, E. Byrne, G. Deuschl, P. D. de Deyn, F. Durif, J. Kulisevsky, T. van Laar, Andrew Lees and 7 more. New England Journal of Medicine, 2004

1,162 citations recorded by the source corpus.

Subfields: Neurology, Pharmacology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/eec1cca3a28e8c6fe1692402f3e200417b7e6a09

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

In Pharmacology

In Psychiatry and Mental health

Citations in the corpus

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop (2006, positive): “The imaging studies have shown possibilities to improve case detection and open label studies have demonstrated the effectiveness of all three generally available CHEIs in DLB and PDD. Placebo controlledtrial data is only available to date for rivastigmine [56,57].”
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. (2009, background): “2 years, and 1% of the prevalent cohort), and their impact on cognitive performance appears to be very modest (Emre et al., 2004).”
Past, Present, and Future of Parkinson’s Disease: A Special Essay on the 200th Anniversary of the Shaking Palsy (2017, neutral): “Uncertainty remains about the potential efficacy of trophic factors in PD.(53) None of these studies delivered the trophic factor in an optimal way, and it is”
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease (2011, background): “patients, more patients on rivastigmine reported tremor as an AE.(45) Worsening of tremor occurred in some patients treated with galantamine.”
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. (2018, background): “…inhibitors should be used as the first-line treatment for cognitive decline (attention and cognitive fluctuations), psychiatric symptoms (visual hallucinations, apathy, and anxiety), and sleep difficulties in both DLB and PDD (Samuel et al. 2000; Emre et al. 2004; Wesnes et al. 2005).”
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline (2007, neutral): “There were, however, no significant differences between rivastigmine and placebo in objectively measured motor scores [223] (I).”
Dual tasking, gait rhythmicity, and Parkinson's disease: Which aspects of gait are attention demanding? (2005, background): “Cholinesterase inhibitors have been shown to improve executive function and attention in PD patients with dementia (Giladi et al., 2003; Emre et al., 2004), but the effects on nondemented patients with PD and on gait and fall risk remain to be determined.”
Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline (2008, methodology): “One study (52) of patients with Parkinson dementia found significant improvement as measured with the Alzheimer’s Disease Clinical Scale.”